Table 1.
All compounds assayed at 1 µM in 384 well plate. Compounds affect steps promoted by HMG (HMGCoA reductase), Δ8–7, (Δ8–7 isomerase), DR24 (DHCR24 reductase) or CYP51 (CYP).
Activity confirmed in human fibroblasts (control or SLOS).
Compound not in NIH Clinical Collection.
See ref 59.
Lanosterol increase in both deficient Neuro2a and fibroblasts.
Decrease of all sterol intermediates.
See ref 60.